Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

Wyeth is now a wholly owned subsidiary of Pfizer20 enrolled

Overview

The purpose of this study is to evaluate the effects of multiple doses of DVS SR and duloxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Depression Depressive Disorder Depressive Disorder, Major

Interventions

desvenlafaxine SRDRUG

desipramineDRUG

duloxetineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

1. Healthy men and women between 18 to 55 years of age. 2. Healthy as determined by the investigator on the basis of medical history and physical examination, laboratory test results, vital signs and a 12-lead electrocardiogram. 3. History of being a nonsmoker for a least 1 year.

Locations (1)

Unnamed facility

Neptune City, New Jersey, United States

Outcomes

Primary Outcomes

The primary outcome of the study is to evaluate the effects of multiple doses of DVS SR and duloxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.